New Technologies and Challenges of Novel Virus Detection

References

1. 1.↵
   1. Khan A. S.

   Testing considerations for novel cell substrates: a regulatory perspective. PDA J. Pharm. Sci. Technol. 2010, 64 (5), 426–431.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Khan A. S.

   Current testing methods and challenges for detection of adventitious viruses. PDA J. Pharm. Sci. Technol. 2011, 65 (6), 627–633.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   http://www.fda.gov/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/vaccinesandrelatedbiologicalproductsadvisorycommittee/ucm288695.htm.
4. 4.↵
   CBER. Guidance for industry: Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. U.S. FDA: Rockville, MD, February 2010.
5. 5.↵
   1. Khan A. S.,
   2. Ma W.,
   3. Ma Y. K.,
   4. Kumar A.,
   5. Williams D. K.,
   6. Muler J.,
   7. Ma H.,
   8. Galvin T.A.

   Proposed algorithm to investigate latent and occult viruses in vaccine cell substrates by chemical induction. Biologicals 2009, 37 (3), 196–201.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Ma H.,
   2. Ma Y. K.,
   3. Ma W.,
   4. Williams D. K.,
   5. Galvin T. A.,
   6. Khan A. S.

   Chemical induction of endogenous retrovirus particles from the Vero cell line of African green monkeys. J. Virol. 2011, 85 (13), 6579–6588.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Ma W.,
   2. Galvin T. A.,
   3. Ma H.,
   4. Ma Y. K.,
   5. Muller J.,
   6. Khan A. S.

   Optimization of chemical induction conditions for human herpesvirus 8 (HHV-8) reactivation with 12-O-tetradecanoyl-phorbor-13-acetate (TPA) from latently-infected BC-3 cells. Biologicals 2011, 39 (3), 158–166.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Khan A. S.,
   2. Lubiniecki A.,
   3. King K.

   Conference Report: PDA/FDA Adventitious agents and novel cell substrates: Emerging technologies and new challenges, Nov. 3-4 2011, Rockville, MD. PDA J. Pharm. Sci. Technol. 2012, 66 (6), 502–511.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Robertson J. S.,
   2. Nicolson C.,
   3. Riley A. M.,
   4. Bentley M.,
   5. Dunn G.,
   6. Corcoran T.,
   7. Schild G. C.,
   8. Minor P.

   Assessing the significance of reverse transcriptase activity in chick cell–derived vaccines. Biologicals 1997, 25 (4), 403–414.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Khan A. S.,
    2. Maudru T.,
    3. Thompson A.,
    4. Muller J.,
    5. Sears J. F.,
    6. Peden K. W.

    The reverse transcriptase activity in cell-free medium of chicken embryo fibroblast cultures is not associated with a replication-competent retrovirus. J. Clin. Virol. 1998, 11 (1), 7–18.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Tsang S. X.,
    2. Switzer W. M.,
    3. Shanmugam V.,
    4. Johnson J. A.,
    5. Goldsmith C.,
    6. Wright A.,
    7. Fadly A.,
    8. Thea D.,
    9. Jaffe H.,
    10. Folks T. M.,
    11. Heneine W.

    Evidence of avian leukosis virus subgroup E and endogenous avian virus in measles and mumps vaccines derived from chicken cells: investigation of transmission to vaccine recipients. J. Virol. 1999, 73 (7), 5843–5851.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Lovatt A.,
    2. Black J.,
    3. Galbraith D.,
    4. Doherty I.,
    5. Moran M. W.,
    6. Shepherd A. J.,
    7. Griffen A.,
    8. Bailey A.,
    9. Wilson N.,
    10. Smith K. T.

    High throughput detection of retrovirus-associated reverse transcriptase using an improved fluorescent product enhanced reverse transcriptase assay and its comparison to conventional detection methods. J. Virol Methods 1999, 82 (2), 185–200.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Cox M. M.,
    2. Hollister J. R.

    FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals. 2009, 37 (3), 182–189.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Liu J.,
    2. Mani S.,
    3. Schwartz R.,
    4. Richman L.,
    5. Tabor D. E.

    Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production. Vaccine. 2010, 28 (5), 1285–1293.

    OpenUrlPubMed
15. 15.↵
    1. Omeir R. L.,
    2. Teferedegne B.,
    3. Foseh G. S.,
    4. Beren J. J.,
    5. Snoy P. J.,
    6. Brinster L. R.,
    7. Cook J. L.,
    8. Peden K.,
    9. Lewis A. M. Jr..

    Heterogeneity of the tumorigenic phenotype expressed by Madin-Darby canine kidney cells. Comp. Med. 2011, 61 (3), 243–250.

    OpenUrlPubMed
16. 16.↵
    1. Onions D.,
    2. Egan W.,
    3. Jarrett R.,
    4. Novicki D.,
    5. Gregersen J. P.

    Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals. 2010, 38 (5), 544–551.

    OpenUrlCrossRefPubMed
17. 17.↵
    http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm335836.htm (Flublok).
18. 18.↵
    http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm328629.htm (Flucelvax).
19. 19.↵
    1. Taliaferro L. P.,
    2. Galvin T. A.,
    3. Ma H.,
    4. Shaheduzzaman S.,
    5. Williams D. K.,
    6. Glasner D. R.,
    7. Khan A. S.

    Evaluation of the broad-range PCR-electrospray ionization mass spectrometry (PCR/ESI-MS) system and virus microarrays for virus detection. Viruses 2014, 6 (5), 1876–1896.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Ma H.,
    2. Galvin T. A.,
    3. Glasner D. R.,
    4. Shaheduzzaman S.,
    5. Khan A. S.

    Identification of a novel rhabdovirus in Spodoptera frugiperda cell lines. J. Virol. 2014, 88 (12), 6576–6585.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Duncan P.

    Summary of the Advanced Virus Detection Technologies Users Group efforts—2013. PDA J. Pharm. Sci. Technol. 2014, (this issue).